BIO-Europe EBD Group BIO BIO-Europe
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

BIO-Europe® 2014 Program Overview

www.ebdgroup.com/bioeurope/program
Sunday, November 2, 2014
14:30–18:00
Frankfurt Pre-Conference Tour

Join our free tour to explore the great Rheingau wine area and enjoy the history of castle Johannisberg.

Experience the oldest form of biotechnology—wine production—with a delicious Riesling wine tasting!

A shuttle bus will pick you up at 14:30 in front of the Maritim Hotel Frankfurt Theodor-Heuss-Allee 3, 60486 Frankfurt am Main and the same shuttle bus will bring you back to Frankfurt, to the Welcome Reception for BIO-Europe.

This tour required registration and is now full.

Rheingau wine area Rheingau wine area Rheingau wine area
Hosted by:
Hessen Trade and InvestHessen Trade and Invest Hessen BiotechHessen Biotech
19:00–21:30
BIO-Europe® Welcome Reception
Johann-Wofgang-Goethe University

All BIO-Europe attendees are cordially invited to join us for a Welcome Reception.

You will be able to pick up your name badge at the welcome reception.

Johann-Wolfgang-Goethe University
Campus Westend
Casino
Grüneburgplatz 1
Frankfurt am Main

Sponsored by:
Hessen Trade and InvestHessen Trade and Invest Hessen BiotechHessen Biotech
House of PharmaHouse of Pharma Infraserv HoechstInfraserv Hoechst
Monday, November 3, 2014
07:45
Portalhaus, Level 0 Foyer
07:45
Hall 1, Level 1, Hall 11.1
Exhibition opens and Continental Breakfast
09:00–10:30
Parallel Workshops
The perfect pitch: Do you have what it takes to win over investors?

Monday, 09:00–10:30
Portalhaus, Level 1, Transparenz 1

Win a one-to-one meeting with a leading life science private equity investor. Members of the audience will have 30 seconds to pitch their company, product, technology or service to a star-studded panel of judges representing at least six life science investment firms. The top picks will be selected for a second round that includes two minutes of presentation and/or Q&A time with the judges. First and second place winners will receive a full 30-minute private followup meeting with the panelist of their choice. Judges will receive a written summary of all participant pitches and their scores, should they wish to follow up on their own. Audience preparation notes:

Participants will be judged on the quality and effectiveness of the overall 30-second pitch. Remember, the primary goal of an elevator pitch is to spark interest for a followup meeting. Pre-workshop coaching is available from the moderator (contact: doug@macbiocom.com). Practice, practice, practice!

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Judges:
  • Mette Kirstine Agger – Managing Partner, Lundbeckfond Ventures
  • Roel Bulthuis – Managing Director, MS Ventures
  • Ann DeWitt – Senior Director of Investments, Sanofi-Genzyme BioVentures, Sanofi
  • Michael Keyoung – Managing Partner, Portola Capital Partners
  • Jack B. Nielsen – Partner, Novo Ventures, Novo A/S
  • Michèle Ollier – Partner, Index Ventures
  • Nancy Sullivan – CEO and Senior Managing Director, Illinois Ventures
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Translational medicine: Transforming research achievements into innovative therapeutic and diagnostic products

Monday, 09:00–10:30
Portalhaus, Level Via, Frequenz 1

The translation of biomedical research into effective therapeutics and diagnostics is the driving factor for innovation in the pharmaceutical industry. Successful translation depends on the right strategy and organization.

This panel presents best practice examples of internationally renowned translational centers. Panelists will discuss their strategies and experiences.

Moderator:
Simone Fishburn – Executive Editor, SciBX, BioCentury Publications Inc.

Panelists:
  • Michael Dalrymple – Director, Business Development, MRC Technology Ltd.
  • Dieter Link – Senior Licensing and Patent Manager, Max-Planck-Innovation GmbH
  • Egenhard Link – Head, Technology Transfer, IST Austria
  • Issi Rozen – Director, Strategic Alliances, Broad Institute
  • Rainer Wessel – Cluster Management Director, Ci3
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
What your patents say about you as an innovator: Leveraging your PR into business opportunities

Monday, 09:00–10:30
Portalhaus, Level Via, Frequenz 2

Biotech innovators must deliver results on many fronts to succeed commercially. The intricacies of patent law are not typically top of mind, yet patents play an essential role in business success. Your patents also tell your business story not only to patent officials and judges but also to investors, regulators, marketers, activists and the rest of the world.

Patents are drafted for global filing, but legislative (and occasionally judicial) reform has not always understood biotechnology. There is fear surrounding the effects of enforcing biotech patent claims, especially when the claims relate to or are derived from higher life forms. When enforcement occurs, innovators also need to account for regional practices. An effective patent strategy can help you establish a successful reputation that is attractive to business partners and investors even prior to any forays before the courts.

We will examine situations where innovators should explain a patent's subject matter to decision makers (and the public at large) to enforce their IP. We will also consider to what extent education or legislative reform is required in various sample jurisdictions. Please join our panel of intellectual property leaders as we discuss best practices for getting biotech patents understood, issued, and enforced around the world as we outline why patents should be a critical part of your PR strategy.

Moderator:
Jay Zakaïb – Partner, Gowlings, Canada

Panelists:
  • Gustavo de Freitas Morais – Partner, Dannemann Siemsen
  • Shahnaz Irani – Principal, Spruson & Ferguson
  • Luc Marengere – Managing Partner, TVM Capital
  • Hubert Witte – Head Patent Department Basel, F. Hoffmann-La Roche Ltd
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45–12:30
Hall 11, Level 0, Hall 11.0
Welcome, Keynotes, and Opening Plenary Discussion
Welcome
Welcome and Opening Remarks

Monday, 10:45–11:15
Hall 11, Level 0, Hall 11.0

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Dr. Rainer Waldschmidt – CEO, Hessen Trade & Invest GmbH
  • David Thomas – Director, Industry Research and Analysis, Biotechnology Industry Organization (BIO)
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Keynote Addresses
Speakers:
Andreas BuschAndreas Busch
Member, Executive Committee;
Head, Global Drug Discovery
Bayer HealthCare
David LoewDavid Loew
Senior VP
Commercial Operations, Europe
Sanofi
Luciano, RossettiLuciano Rossetti
Executive VP,
Head of Global Research and Development,
Member of the Pharmaceutical Executive Committee,
Merck Serono

Opening Plenary Discussion
Biopharma strategy: More focus, more value?

Monday, 11:45–12:30
Hall 11, Level 0, Hall 11.0

Moderator:
Jean-François Formela – Partner, Atlas Venture

Panelists:
  • Andreas Busch – Member, Executive Committee; Head, Global Drug Discovery, Bayer HealthCare
  • David Loew – Senior VP, Commercial Operations, Europe, Sanofi
  • Luciano Rossetti – Executive VP, Head of Global Research and Development, Member of the Pharmaceutical Executive Committee, Merck Serono
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–13:30
Hall 11, Level 0, Foyer Hall 11.0, Restaurant Verdino
Portalhaus, Level Via
Hall 11, Level 1, Hall 11.1
Luncheon
13:30–18:15
Parallel Panel Discussions
Business Development Track
Mind the GAP? Meeting an emerging demand for access to medicines in late-stage clinical trials, prior to commercial launch

Monday, 13:30–14:30
Portalhaus, Level Via, Frequenz 1

Countless patients around the world are in urgent need of new therapeutic alternatives to address a huge degree of unmet medical need. Patient demand, which has been increasingly reported in the news and via social media, can put intense pressure on the physicians treating those patients, and biopharma companies to provide pre-launch access to drugs that are in late-stage clinical trials.

In an area where global regulations are complex and constantly evolving, this panel explores the industry environment, regulatory landscape and the options available around early access, using the new UK Early Access to Medicines Scheme (EAMS) as a case study. It will further discuss the roles that pharma, biotech, regulators, access program providers, and physicians play in bridging the gap between clinical trial results and full commercial availability for a drug, along with the opportunities and challenges that exist in this complex space.

Moderator:
Steve Bates – CEO, BIA

Panelists:
  • Henrik Balle Boysen – Executive Director, HAEi
  • Morgan Conn – Executive Director, Business Development, PTC Therapeutics
  • Mark Corbett – Senior VP, Clinigen GAP
  • Markus Kosch – Commercial Portfolio Lead Oncology, Europe, Africa and Middle East, Pfizer
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Access to funding for European companies

Monday, 14:45–15:45
Portalhaus, Level Via, Frequenz 1

A dynamic biotech sector depends on a vital stock market, not only as a source of fresh money, but also as an exit route for investors. But whereas the US biotech sector relies on a central platform, the European stock market is highly diverse. As more and more EU companies set up shop in the US or go for their IPO, what does this mean for EU companies looking for access to capital? Out-licensing products and a reliance on government grants are two ways they are bridging the gap, but it's not enough for many of these companies. Alternative sources of capital are of increasing interest. We sit down with a variety of investors from both sides of the pond to explore funding options for these companies.

Moderator:
Boris Mannhardt – CEO, BIOCOM AG

Panelists:
  • Siegfried Bialojan – Head, Ernst & Young Life Science Center, Ernst & Young
  • Paul J. Hadden – Principal, HealthCare Royalty Partners
  • Matthias Kromayer – Board Member, MIG Verwaltungs AG
  • Naveed Siddiqi – Partner, Edmond de Rothschild Investment Partners
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Early market access

Monday, 16:00–17:00
Portalhaus, Level Via, Frequenz 1

Adapted licensing seeks to maximize the positive impact of new active substances to public health, and will therefore become a major strategy for pharmaceutical companies. This session covers the regulatory environment of AL, as well as the regulatory and reimbursement regime of existing pre-market access (named patient, compassionate use, ATU) in pharmaceutical key markets in the EU.

Moderator:
Joe Damond – Senior VP, International Affairs, Biotechnology Industry Organization (BIO)

Panelists:
  • Benjamin Gannon – Senior Director, Government Affairs and Public Policy, Vertex Pharmaceuticals
  • Alexander Natz – Secretary General, EUCOPE
  • Cord Willhöft – Partner, Life Sciences Regulatory, Fieldfisher
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
The right deal at the right time: How are sell-side dealmakers getting it right, or wrong, in today's environment?

Monday, 17:15–18:15
Portalhaus, Level Via, Frequenz 1

During this session we will take a look at the sell-side of the dealmaking table. We will take the pulse of senior decision makers from biotech and pharma to discuss what makes certain transactions more successful than others. Several CEOs from clinical-stage biotech companies will give a firsthand account of their strategies, challenges faced and outcomes of the partnering experience, while pharma executives weigh in on the unique attributes they look for in a successful deal.

Moderator:
Peter Homberg – Partner, Dentons

Panelists:
  • Jennifer Laird – VP and Regional Head ACE Global External R&D, Eli Lilly and Company
  • Michael Martin – Senior Director, Global Licensing and Business Development, Takeda
  • Elias Papatheodorou – Chief Business Officer, Covagen
  • Christian Wandersee – CEO, vasopharm GmbH
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Spotlight Track
Late stage complications in diabetes

Monday, 13:30–14:30
Portalhaus, Level Via, Frequenz 2

Moderator:
Tomas Landh – Director, Strategy and Innovation Sourcing, Diabetes Research Unit, Novo Nordisk

Panelists:
  • Gael Hedou – CEO, Relief Therapeutics
  • Stan Kim – Business Development Manager, EyeGene, Inc.
  • Jochen Maas – General Manager, R&D Germany, Sanofi-Aventis
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Next generation cancer therapies: What types of partnerships will guide development of targeted and individualized immunotherapies, CSC drugs and other new cancer treatments?

Monday, 14:45–15:45
Portalhaus, Level Via, Frequenz 2

The drug development community is flush with new approaches to treating hematological cancers, solid tumors, and other cancer-associated illnesses. New companies are being formed every day and virtually every large pharma and large cap biotech company has a focused effort in cancer immunotherapies. The traditional path for developing these new treatments may not be relevant given the unique requirements of some of these new treatments. This may necessitate different types of deal structures and development milestones and the involvement of new stakeholders such as medical centers and other groups. This session will examine the new world of cancer drug development and the implications for partnerships and product development strategies.

Moderator:
Morrie Ruffin – Managing Partner, Adjuvant Partners

Panelists:
  • Anne Altmeyer – VP, Business Development and Licensing, Novartis Oncology
  • Rachel B. Cervantes – Director, Business Development, Inovio Pharmaceuticals
  • Michel Detheux – Co-Founder and CEO, iTeos Therapeutics
  • Mohamed Ragab – VP, Search and Evaluation, Oncology, Bristol-Myers Squibb
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Corporate views on personalized immune intervention

Monday, 16:00–17:00
Portalhaus, Level Via, Frequenz 2

Personalized medicine has the potential to transform medical treatment as the mechanisms of disease and treatment become better understood. Antibodies, the dominant class of stratified immunotherapies, already amount to more than EUR 35 billion in sales worldwide.

The presentations and panel discussion will focus on current and future developments in personalized immune intervention markets, potential risks, and business strategies to realize the full market potential.

Moderator:
Anna C. Eichhorn – CEO, Humatrix

Panelists:
  • Richard Batrla – Global Medical Leader Companion Diagnostics, Medical and Scientific Affairs, Roche Professional Diagnostics, Roche Diagnostics International AG
  • Cedrik M. Britten – VP, R&D, BioNTech RNA Pharmaceuticals GmbH
  • Thomas Henkel – CEO and Co-Founder, Targos Molecular Pathology GmbH
  • Michael Wolf – Head Emerging Immunotherapies, ImmunoOncology, Merck Serono
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Advancements in orphan drugs

Monday, 17:15–18:15
Portalhaus, Level Via, Frequenz 2

Moderator:
Hubert Birner – Managing Partner, TVM Life Science Management Inc.

Panelists:
  • Jörn Aldag – CEO, uniQure N.V.
  • Scott Clarke – VP, Business Development and Scientific Licensing, BioMarin Pharmaceutical
  • Adi Hoess – CEO, Affimed Therapeutics
  • Jeremy P. Springhorn – VP, Corporate Development, Alexion Pharmaceuticals
  • John A. Tagliamonte – Chief Business Officer, Oxyrane
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Pharma Presentations
Boehringer Ingelheim Licensing

Boehringer Ingelheim Licensing
Monday, 13:30–13:45
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Vishal Kapur – Global Head of Respiratory Business Development & Licensing, Boehringer Ingelheim
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alexion Pharmaceuticals

Alexion Pharmaceuticals
Monday, 13:45–14:00
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Jeremy P. Springhorn – VP, Corporate Development, Alexion Pharmaceuticals
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Janssen Pharmaceutical Companies of Johnson & Johnson

Janssen Pharmaceutical Companies of Johnson & Johnson
Monday, 14:00–14:15
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Ann Connolly – Senior Director, New Ventures, Johnson & Johnson Innovation, London
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Merck Serono, a division of Merck KGaA

Merck Serono, a division of Merck KGaA
Monday, 14:15–14:30
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Philippe Lopes-Fernandes – Senior VP, Head of Global Licensing & Business Development, Merck Serono
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:30–14:45
MSD

MSD
Monday, 14:30–14:45
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Iain Dukes – Senior VP, Business Development and Licensing
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:45–15:00
AstraZeneca

AstraZeneca
Monday, 14:45–15:00
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Eric Victory – VP, Biotech & Partnering Strategy; Head for Cardiovascular, Metabolic and Infectious Disease, AstraZeneca
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:00–15:15
AbbVie

AbbVie
Monday, 15:00–15:15
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Anthony G. Brazda – Director, Licensing & Acquisitions, AbbVie
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Novartis Pharma

Novartis Pharma
Monday, 15:15–15:30
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Markus Kalousek – Global BD&L, S&E Franchise Head, Integrated Hospital Care, Novartis Pharma
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–15:45
Roche

Roche
Monday, 15:30–15:45
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Stephen Sands – Commercial Lead Oncology/Immunology, Roche
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:45–16:00
Genentech

Genentech
Monday, 15:45–16:00
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Alexander Schuth, MD – Director, Genentech Partnering, Genentech
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co., Ltd.
Monday, 16:00–16:15
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Philipp R. Hoffmann – Senior Director, Business Development & Licensing, Daiichi Sankyo Europe GmbH
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:15–16:30
Pfizer

Pfizer
Monday, 16:15–16:30
Portalhaus, Level 1, Transparenz 1

Speaker:
  • James Eshelby – Senior Director, Worldwide Business Development, Pfizer
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
GlaxoSmithKline

GlaxoSmithKline
Monday, 16:30–16:45
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Jon Ellis – VP, Worldwide Business Development, GlaxoSmithKline
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bayer HealthCare Pharmaceuticals

Bayer HealthCare Pharmaceuticals
Monday, 16:45–17:00
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Nigel Sheail – Head of Business Development and Licensing, Bayer HealthCare
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Eli Lilly and Company

Eli Lilly and Company
Monday, 17:00–17:15
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Tim Luker – Director, External Innovation, Eli Lilly and Company
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:15–17:30
Sanofi

Sanofi
Monday, 17:15–17:30
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Dr. Harald Pacl – R&D Strategy, Science Policy & External Innovation, Sanofi
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:30–17:45
Amgen

Amgen
Monday, 17:30–17:45
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Norbert Prenzel – Licensing Director, External Research and Development, Amgen
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Takeda Pharmaceutical Company Ltd.

Takeda Pharmaceutical Company Ltd.
Monday, 17:45–18:00
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Natalie Mirutenko – Senior Director, Search & Evaluation, Takeda Pharmaceutical Company Ltd.
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
18:00–18:15
Novo Nordisk

Novo Nordisk
Monday, 18:00–18:15
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Tomas Landh – Director, Strategy and Innovation Sourcing, Diabetes Research Unit, Novo Nordisk
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bristol-Myers Squibb

Bristol-Myers Squibb
Monday, 18:15–18:30
Portalhaus, Level 1, Transparenz 1

Speaker:
  • Lubor Gaal – Executive Director, Europe, Strategic Transactions Group , Bristol-Myers Squibb
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:30–18:30
One-to-one Meetings ►
18:00–18:45
Hall 11, Level 1, Hall 11.1
Exhibit Hall Hospitality Reception

Join us at booth #29 and learn how the industry's largest network of life science professionals can increase your business opportunities.

Hosted by:

partnering360 partnering360
19:00–22:30
Evening Networking Reception with Buffet-style Dinner
Jahrhunderthalle Frankfurt

Jahrhunderthalle Frankfurt
Pfaffenwiese 301
65929 Frankfurt | (map)

Jahrhunderthalle Frankfurt is an established international venue, a landmark symbolizing economic and cultural attainment in the 20th century. Designed by Friedrich Wilhelm Krämer and completed in 1963, Jahrhunderthalle Frankfurt is a commanding presence and a manifesto of modern style which owes its enduring contemporary appeal to the elegance of its flowing lines. This cultural and conference center hosts fine ballets, rock stars, and musicals as well as business events.

18:45–19:15 Shuttle buses depart from Portalhaus Messe Frankfurt to the evening event.
21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.

Sponsored by:

Sanofi Sanofi
Tuesday, November 4, 2014
07:45
Portalhaus, Level 0 Foyer
07:45
Hall 11, Level 1, Hall 11.1
Exhibition opens and Continental Breakfast
09:00–11:45
Spotlight on SMEs
Innovative funding for SMEs in Europe

Tuesday, 09:00–10:30
Portalhaus, Level Via, Frequenz 1

With the shortage of early stage life sciences funding, the role of government in funding the next generation of cures is becoming increasingly important. In January 2014, the European Union launched the SME instrument, a multibillion euro funding program dedicated to all innovative small and medium-sized enterprises (SMEs) in Europe which is very similar to the US SBIR program. The session will provide an overview of this program and will also introduce other European initiatives relevant to SMEs. A special focus on the Innovative Medicines Initiative—the Public Private Partnership (PPP) between the European Commission and the European Pharmaceutical industry—will be made.

The session will have three presentations. Two presentations will be made by high-level representatives from the EU (European Commission – DG Research and Innovation – Health Directorate) and the IMI. Additionally, one presentation will be made by a European small business which will share its experiences in leveraging government funding to move their technology towards clinical adoption and commercialization.

Speakers:
  • Michael Burnet – CEO, Synovo GmbH
  • Colm Carroll – Scientific Project Manager, Innovative Medicines Initiative
  • Philippe Cupers – Deputy Head of Strategy Unit, Health Research Directorate, DG Research and Innovation, European Commission, Brussels, Belgium
  • Anton Ussi – Head of Operations, EATRIS
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Optimizing your clinical trials for better outcomes and best use of available funding

Tuesday, 10:45–11:45
Portalhaus, Level Via, Frequenz 1

Emerging biopharmaceutical companies constitute one of the true hubs of innovation in today's drug development ecosystem. However, most operate under constrained resources in terms of management bandwidth and available capital. In addition, many companies may have only one asset in clinical development. Therefore, maximizing results in development is essential to continued success. While emerging biopharmas have deep scientific expertise around a specific therapeutic area or indication, in-house clinical trial experience can be limited. This panel is intended to help emerging biopharma companies explore some of the key steps they can take to accelerate timelines and improve their probability of successfully demonstrating value. Our experienced panelists will discuss how you can:

  • design your trials, from the very start, with the end in mind to gather the necessary evidence
  • understand your product's realistic target profile and patient populations earlier in the development process
  • leverage genetic profiling to better identify and access the right patients
  • accelerate critical study start-up activities to improve overall timelines
  • utilize tailored risk-based monitoring approaches to maximize efficiency
  • explore the advantages of using adaptive trial design
  • partner with experts more effectively to take greater advantage of multiple data sources, analytics and global relationships

Moderator:
Jeremy Broadis – VP, Commercial, International, Quintiles

Panelists:
  • Josh Rose – VP, Enterprise Offering Development, Quintiles
  • Brad Smith – VP, Translational Medicine, Center for Integrated Drug Development, Quintiles
  • Christoph Schnorr – VP, Drug Development Consulting Europe, Quintiles
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:00–18:00
Company Presentations ►
08:00–18:30
One-to-one Meetings ►
12:00–13:00
Keynote Plenary Discussion
A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2014

Tuesday, 12:00–13:00
Hall 11, Level 0, Hall 11.0

Moderator:
David Stubbs – Founding Partner and Managing Director, Inverness Advisors

Panelists:
  • Iain Dukes – Senior VP, Business Development and Licensing, Merck
  • Shaun Grady – VP, Business Development Operations, AstraZeneca
  • Adam Keeney – Global Head, External Innovation Operations Strategy, Science Policy and External Innovation, Sanofi
  • James Sabry – Senior VP, Global Head of Partnering, Genentech
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:00–14:00
Hall 11, Level 0, Foyer Hall 11.0,
Restaurant Verdino
Portalhaus, Level Via
Hall 11, Level 1, Hall 11.1
Luncheon
15:00–16:40
Academic Innovators™ Showcase

Tuesday, 15:00–16:40
Portalhaus, Level 1, Transparenz 2

Join us for the Academic Innovators™ presentation track as we work with industry leaders to shine a spotlight on the many scientific advances with strong translational potential being made in the academic world.

Organizations:
  • Cincinnati Children's Hospital Medical Center
  • Goethe University Frankfurt, Institute of Pharmaceutical Chemistry
  • Goethe University Frankfurt, Institute of Clinical Pharmacology
  • imec
  • Los Angeles Biomedical Research Institute
  • McGill University
  • MRC Technology Ltd.
  • Northwestern University – Feinberg School of Medicine
  • TTFactor srl
  • TI Pharma
  • University of Wuerzburg
BIO-Europe® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:45–18:45
Hall 11, Level 1, Hall 11.1
Exhibit Hall Hospitality Receptions

Hosted by:

ABA - Invest In Austria ABA - Invest In Austria
at the Austrian Booth 74
Datamonitor Datamonitor at Booth 50
Boehringer Ingelheim Boehringer Ingelheim at Booth 40
Hessen Trade & Invest Hessen Trade & Invest Infraserv Hoechst Infraserv Hoechst Wirtschaftsforderung Frankfurt Wirtschaftsforderung Frankfurt at Booth 58
Life Science Nord Life Science Nord at Booth 55
Lonza Lonza at Booth 21
19:00–22:30
Evening Networking Reception with Buffet-style Dinner
Gesellschaftshaus Palmengarten

Gesellschaftshaus Palmengarten
Palmengartenstraße 11
60325 Frankfurt am Main | (map)

The Gesellschafthaus—Society House—at the edge of the Palmengarten, the green heart of the city, dates from 1870 with the Festsaal (Ballroom) as its centerpiece. With two classical chandeliers and the beautiful historical parquet floor, this room is a pleasure to behold. The rooms combine distinctive original designs and modern features, and each has a spectacular view of the artistically-designed flower garden as well as the idyllic Palmengarten in all its verdant splendor.

Sponsored by:

Bayer HealthCare

18:45–19:15 Shuttle buses depart from Portalhaus Messe Frankfurt to the evening event.
21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.

Wednesday, November 5, 2014
07:45
Portalhaus, Level 0 Foyer
07:45
Hall 11, Level 1, Hall 11.1
Exhibition opens and Continental Breakfast
9:00–13:00 Company Presentations ► 8:00–17:00
One-to-one Meetings ►
13:00–14:00
Hall 11, Level 0, Foyer Hall 11.0, Restaurant Verdino
Portalhaus, Level Via
Hall 11, Level 1, Hall 11.1
Luncheon
16:30
Hall 11, Level 1, Hall 11.1
Closing Reception
Arrow Up


© 2009–2014 EBD GmbH
BIO-Europe EBD Group BIO BIO-Europe